NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
← catalyst calendarSponsored by Nkarta, Inc. (industry) · NKTX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
6
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-20 | actual | When the study began enrolling |
| Primary completion | 2025-03-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, Non-Hodgkin
- B-cell Acute Lymphoblastic Leukemia
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Indolent Lymphoma
- Waldenstrom Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Aggressive Lymphoma
- Large-cell Lymphoma
Intervention
- Biological: NKX019
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured 30 days after last dose of NKX019
Proportion of subjects experiencing dose-limiting toxicities of NKX019
measured 28 days from first dose of NKX019
Objective response rate to NKX019 in Part 2
measured Primary assessment: 28 days after the first dose of NKX019 followed up to 2 years after the last dose of NKX019]
Permalink · NKTX's whole pipeline · Catalyst calendar · Every registered study · What changed